5/22/15 07:32 | 5/20/15 | BLPH | Bellerophon Therapeutics, Inc. | | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | NJ | O | Chief Sc | P | 6 | 8.40 | 0 | 1 | 4 | 19 | D | | | | -4 | -9 | -3 | 4 | 10 | 0 | 3 | -16 | -39 | -68 | -86 |
2/23/15 21:39 | 2/19/15 | BLPH | Bellerophon Therapeutics, Inc. | | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | NJ | O | Chief Sc | P | 144 | 12.00 | 3 | 12 | 188 | 18 | D | | | | | | | | 2 | -2 | 25 | 6 | -6 | -44 | -78 |
5/11/10 14:14 | 5/11/10 | LGND | Ligand Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | CA | O | V-P,Disc | P | 10 | 1.63 | 0 | 6 | 7 | 102 | D | -51 | -46 | -13 | 6 | -4 | -7 | -12 | -10 | 0 | -2 | -6 | -3 | 1 | 10 |
5/9/08 13:53 | 5/9/08 | LGND | Ligand Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | CA | O | V-P,Disc | P | 10 | 3.36 | 0 | 3 | 9 | 37 | D | -61 | -51 | -37 | -21 | -13 | -17 | -18 | -9 | 0 | 4 | -7 | -12 | -57 | -10 |
8/30/07 19:04 | 8/30/07 | LGND | Ligand Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | CA | O | V-P,Disc | P | 12 | 6.19 | 1 | 2 | 17 | 14 | D | 3 | -15 | -29 | -8 | -11 | 0 | 0 | -7 | 0 | -1 | -15 | -28 | -47 | -47 |
12/19/06 18:51 | 12/15/06 | LGND | Ligand Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | CA | O | V-P,Disc | M.d | 39 | 7.25 | 1 | 5 | | 1 | D | -8 | 1 | 22 | 7 | 0 | 2 | 3 | 1 | 0 | 1 | 2 | -4 | -13 | -37 |
12/19/06 18:51 | 12/15/06 | LGND | Ligand Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | CA | O | V-P,Disc | S.d | -60 | 11.23 | 1 | -5 | -91 | 1 | D | -8 | 1 | 22 | 7 | 0 | 2 | 3 | 1 | 0 | 1 | 2 | -4 | -13 | -37 |
11/12/04 17:11 | 11/11/04 | LGND | Ligand Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Meglasson Martin | CA | O | V-P,Disc | P | 4 | 8.82 | 2 | 1 | New | 1 | D | 29 | -29 | -48 | 4 | -12 | 3 | 4 | -6 | 8 | 19 | 36 | 19 | -34 | -10 |